| Identification | Back Directory | [Name]
2,4-Quinazolinediamine, N4-cyclohexyl-N2-(3,4-difluorophenyl)- | [CAS]
911678-60-9 | [Synonyms]
2,4-Quinazolinediamine, N4-cyclohexyl-N2-(3,4-difluorophenyl)- | [Molecular Formula]
C20H20F2N4 | [MOL File]
911678-60-9.mol | [Molecular Weight]
354.4 |
| Chemical Properties | Back Directory | [Boiling point ]
531.6±60.0 °C(predicted) | [density ]
1.330±0.06 g/cm3(Temp: 20 °C; Press: 760 Torr)(predicted) | [storage temp. ]
2-8°C | [solubility ]
DMSO: 2mg/mL, clear | [form ]
powder | [pka]
7.38±0.30(predicted) | [color ]
white to beige |
| Hazard Information | Back Directory | [Biological Activity]
Gs-biasedβ2 subtype-selective adrenergic receptor (AR) negative allosteric modulator (NAM) th at inhibits β-arrestin recruitmentbut not Gs coupling to β2AR.
DFPQ is a Gs-biasedβ2 subtype-selective adrenergic receptor (AR) negative allosteric modulator (NAM) th at inhibits β-arrestin recruitment (IC50 = 600 nM; 30-min DFPQ pretreatment prior to 12-min 1 μM ISO induction)but not Gs coupling to β2AR (30-min 10 μM DFPQ pretreatment prior to 10-min 1 μM ISO-induced cAMP production). DFPQ effectively inhibits agonist-induced β2AR phosphorylation (IC50 = 2.6 μM; 30-min DFPQ pretreatment prior to 10-min 1 μM ISO induction) and internalization (100% inhibition by 30-min 10 μM DFPQ prior to 1h 10 μM ISO) and protects against the functional desensitization of β-agonist-mediated regulation in cell and tissue models with minimal effects on β1AR. |
|
| Company Name: |
Merck KGaA
|
| Tel: |
21-20338288 |
| Website: |
www.sigmaaldrich.cn |
| Company Name: |
Biorbyt Ltd.
|
| Tel: |
+44 (0)1223 859 353 |
| Website: |
http://www.biorbyt.com |
|